HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
11 September 2022Blood marker which predicts the risk of osteoporotic hip fractures in older men
12 September 2022HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
